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A liver transplantation is a treatment option in selected patients with hepatocellu-
lar carcinoma (HCC). Despite the adequate selection of candidates, recurrences 
of HCC may still develop. Solitary extrahepatic metastasis from HCC after a liv-
er transplantation is rare. Here we report two cases of HCC demonstrated extra-
hepatic recurrence to the adrenal gland and spleen, respectively, within one year 
after a liver transplantation. Since the treatment of solitary extrahepatic metastasis 
from HCC after a liver transplantation is not standardized, surgical resection was 
performed. In the case of HCC adrenal metastasis, innumerable intrahepatic me-
tastases were found two months after the adrenalectomy. And 16 months after ad-
renalectomy, the patient expired due to tumor progression and hepatic failure. In 
the case of HCC splenic metastasis, postoperative radiation therapy was per-
formed. However, two recurrent HCC nodules were found 15 months after the 
splenectomy and received transarterial chemoembolization (TACE). And 29 
month after the splenectomy, the patient also expired as same causes of former 
patient.  
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INTRODUCTION  
There are several treatments for hepatocellular carcinoma (HCC), and a liver 
transplantation can be performed in a selected group of patients as such a treat-
ment. After the introduction of the Milan and University of California at San Fran-
cisco (UCSF) criteria, the candidates for a liver transplantation have been expand-
ed. The use of a specific selection criteria has been shown to improve tumor-free 
survival in patients undergoing a liver transplantation for HCC.1-3 However, de-
spite the adequate selection of candidates, recurrences of HCC may still develop 
and result in death.4,5 The adrenal gland is a common target organ of hematoge-
nous metastasis from HCC6 however, the spleen has been rarely reported as a met-
astatic site of HCC. We report two cases of solitary extrahepatic metastasis from 
HCC after a liver transplantation treated with surgical resection.
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crolimus after the liver transplantation.
Eleven months post-transplantation, a CT scan revealed a 
solitary left adrenal mass, 3.5 × 2.3 cm in size, without any 
other recurrent lesions (Fig. 1A). The laboratory values 
showed hemoglobin of 10.2 g/dL, WBC of 3,270/μL, plate-
let count of 119,000/μL, albumin of 4.5 g/dL, AST/ ALT of 
32/15 IU/L, total bilirubin of 0.5 mg/dL, prothrombin time 
of 10.7 sec, and AFP of 6.02 IU/mL. The patient was in a 
good performance status and underwent a left adrenalecto-
my with retroperitoneal approach in April 2007. A multi-
nodular grayish-brown, soft-to-friable solid mass was gross-
ly noted. It was well demarcated, measuring 5 × 3.5 cm in 
size. Tumor emboli were present in the blood vessels con-
necting to the mass (Fig. 1B). The pathological examination 
demonstrated metastatic HCC without metastatic lymph 
nodes retrieved from around the aorta and the left renal ves-
sels (Fig. 1C). There were no immediate complications dur-
ing recovery. Immunosuppressive therapy (Tacrolimus) 
continued following the adrenalectomy.
However, a follow-up CT scan taken two months after 
the adrenalectomy revealed innumerable intrahepatic arteri-
al enhancing nodules consistent with HCC. There were no 
recurrent lesions at the site of the adrenalectomy. The pa-
tient received systemic adriamycin chemotherapy with sub-
sequent transarterial chemoembolization. The intrahepatic 
recurrent tumors were not controlled, although chemothera-
py was performed. The patient expired 16 months after the 
adrenalectomy due to liver failure. 
Case 2
A 63-year-old man who was a carrier of HBV for 30 years 
was admitted for a ruptured HCC located in segments VIII 
of the liver in August 2004. He belonged to Child-Pugh 
class A. He was treated three consecutive times with TACE. 
The patient then underwent a central bisectionectomy in 
February 2005 due to a remaining viable tumor (Fig. 2A). 
The tumor was 5.7-cm in diameter and the resection margin 
was tumor-free with a distance of 3.5 cm (Fig. 2B). It was 
compatible with HCC and was composed of 60% necrosis 
due to TACE. Vascular invasion was not found. Sixteen 
months after the operation, another 1.5 cm-sized recurrent 
HCC on segment VII was found, and the AFP level in-
creased to 54.53 IU/mL. He was treated with TACE how-
ever; the remaining viable tumor was still detected with an 
increase in size. Then the patient underwent a cadaver do-
nor liver transplantation in November 2006 in China. He 
thereafter took Tacrolimus for immunosuppression. Four 
CASE REPORT
Case 1
A 71-year-old man with HCV hepatitis was diagnosed with 
HCC in 2002. He was treated with radiofrequency ablation 
and transarterial chemoembolization (TACE) for the HCC 
at another hospital. When he was referred to our hospital in 
December 2005, a CT scan demonstrated innumerable tiny 
intrahepatic HCC nodules. He belonged to Child-Pugh 
class A, and the alpha-fetoprotein (AFP) level was mea-
sured at 87.96 IU/mL. After a treatment with two cycles of 
intrahepatic arterial cisplatin and systemic 5-FU chemo-
therapy, he underwent a cadaver donor liver transplantation 
in March 2006 in China, although he met neither Milan nor 
UCSF criteria. He took Pegylated interferon alpha and Ta-
Fig. 1. A CT scan reveals a newly-developed solitary left adrenal mass, 
which was 3.5 × 2.3 cm in size, homogenous, and well-demarcated, sug-
gesting HCC metastasis (A). Pathologic specimen following adrenalectomy 
(B) and microscopic exam, Hematoxylin & Eosin stain, ×100 (C).
A
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metastatic HCC (Fig. 3C and D). Because the lesion invad-
ed the perisplenic space, the patient received radiation ther-
apy on the splenectomy site following an uneventful post-
operative recovery. The radiation dosage was 50.4 Gy. The 
patient demonstrated no evidence of recurrence for 15 
months. The patient received only adjuvant radiation thera-
py without any other treatment modality. However, a fol-
low-up CT scan taken 15 months after the splenectomy 
demonstrated two nodular lesions in segment VI of the liv-
er compatible with HCCs. He then received TACE for 4 
times. However, he was in the progressive disease status 
and was expired 29 months after the splenectomy.
months after the liver transplantation, a newly-developed 3 
cm-sized heterogeneous mass was found in the hilum of the 
spleen (Fig. 3A and B). The laboratory values showed he-
moglobin of 10.7 g/dL, WBC of 3400/μL, platelet count of 
146,000/μL, albumin of 4.4 g/dL, AST/ ALT of 18/9 IU/L, 
total bilirubin of 0.4 mg/dL, prothrombin time of 11.0 sec, 
and AFP of 2.15 IU/mL. The patient was closely observed 
for three months, and a splenectomy was performed in July 
2007 due to a mass growth without evidence of intrahepatic 
recurrence or distant metastasis. A well-defined, white, sol-
id mass measuring 6 × 5 × 4.5 cm was found. It was partial-
ly encapsulated and was pathologically compatible with 
A B
Fig. 2. A CT scan demonstrates a ruptured HCC located in segment VIII of the liver (A). Central bisectionectomy was performed following 
TACE, and the mass was a 5.7 cm HCC with 60% necrosis (B). HCC, hepatocellular carcinoma.
C
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D
B
Fig. 3. A newly-developed, 3 cm-sized heterogeneous mass was found in the hilum of the spleen after liver transplantation (A and B). 
Pathologic specimen following splenectomy (C) and microscopic exam, Hematoxylin & Eosin stain, ×40 (D). 
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In the cases of solitary splenic metastasis of HCC, it is 
also difficult to predict the prognosis. Because metastatic 
splenic tumors are usually detected as a part of disseminat-
ed hematogenous metastasis with multi-organ involvement, 
isolated splenic metastasis is exceedingly rare.14 The surviv-
al benefit of a splenectomy for a solitary metastatic splenic 
tumor is unknown and the disease control effect will be 
evaluated. However, with more aggressive management of 
metastatic tumors, the increase to perform splenectomy as a 
treatment of solitary splenic metastasis during the past de-
cade might be expected to continue.15
In conclusion, the survival benefit of surgical resection in 
the management of isolated extrahepatic metastases of 
HCC is questionable due to its rarity. Surgical resection is a 
treatment option with low morbidity that may offer a chance 
for long-term survival in selected patients without poor 
prognostic factors and whose intrahepatic tumors are con-
trolled. Surgical treatment can be an option to treat extrahe-
patic solitary metastasis from HCC. 
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